Last reviewed 2026-05-24 · How we verify

Ethizone (SUBATHIZONE)

Phase 2 active Small molecule ✓ Verified May 2026

Ethizone (generic name: SUBATHIZONE) is a subathizone drug. It is currently in Phase 2 development.

Ethizone is thought to work by interacting with a specific cellular target, although the exact nature of this interaction is not well understood.

Ethizone is a small molecule with the synonyms NSC-718, SUBATHIZONE, and SUBATIZONA. Its modality is classified as a small molecule.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SUBATHIZONE
Drug class	subathizone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells as locks on a door. Ethizone is like a key that fits into one of these locks, but we don't know which lock it is or how it works once it's inside. This interaction may help to regulate various bodily functions, but more research is needed to understand the details.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ethizone CI brief — competitive landscape report
Ethizone updates RSS · CI watch RSS

Frequently asked questions about Ethizone

What is Ethizone?

Ethizone (SUBATHIZONE) is a subathizone drug.

How does Ethizone work?

Ethizone is thought to work by interacting with a specific cellular target, although the exact nature of this interaction is not well understood.

What is the generic name of Ethizone?

SUBATHIZONE is the generic (nonproprietary) name of Ethizone.

What drug class is Ethizone in?

Ethizone belongs to the subathizone class. See all subathizone drugs at /class/subathizone.

What development phase is Ethizone in?

Ethizone is in Phase 2.

Drug class: All subathizone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing